
ã¯ã¡ã¿ã€ãšã¯ã¹ãª
ãè¬ãæ£è ããã«ãæž¡ããããšãã«
ãç§ãã¯ã¡ã¿ã€é£ã¹ãŠã倧äžå€«ãããïŒé£²ãã§ãè¬ãšã®é£²ã¿åããã¯å€§äžå€«ããªãšæã£ãŠã
ãšãã質åãããã ããŸããã
ãã¯ã¡ã¿ã€ã£ãŠããããããšå°ãèããŸããããã¯ã¡ã¿ã€ãšèšãã°âçãâãâãâçãâãšèšãã°âç³âãâãâç³âãšããã°âç³å°¿ç âãšããçºæ³ãããã®ãšãã¯æãæµ®ãã³ãŸããã§ããã
ããšãã調ã¹ãŠã¿ããšãåœç£ã®ã¯ã¡ã¿ã€ïŒã¢ã«ã·ã¢èãšã¬ã³ã²èïŒã¯äœGIã®ãã®ãå€ãããã§è¡ç³å€ã®äžæãç·©ãããªé£åã«è©²åœããããã§ããã
ä»åã®æ£è ããã«ã€ããŠã¯ç³å°¿ç ã®åºç€çŸæ£ããªããè¡å§ãèè žç³»ã®è¬ã®ã¿ã§ãã£ããããããããã¯ã¡ã¿ã€ã«çžäºäœçšãªããŠããã®ãïŒãšããæããããç¹ã«åé¡ãªãã§ããšã®åçã§çµãã£ãŠããŸã£ãŠããŸãã
ããããèé¢ä¿ã§ããã¯ã¡ã¿ã€ã以å€ã«ãããããŒã€ã«ãŒãªãŒããããããªã¹ããããã«ãããŒããªã©ãããããªååãåºãŠããŸããããã®éãã«ã€ããŠãã¯ã£ããçè§£ããŠããŸããã§ããã
ããã§å補åã®ç¹é·ãšã¯ã¹ãªãšã®é£²ã¿åããã«ã€ããŠèããŠã¿ãããšæããŸãã
ãã®åã«ããªãä»åçªç¶æ£è ããããã¯ã¡ã¿ã€ãé£ã¹ããããšæã£ãã®ããçåã ã£ãã®ã§ã€ã³ã¿ãŒãããã§æ€çŽ¢ãããšãã
2020幎3æ10æ¥æŸéã®ãæä¿®ã®ä»ã§ããè¬åº§ãã§ãããããåãäžããããŠãããããŠã€ã«ã¹ã现èãæéããããæè广ãã®è©±ããããŠããããã§ãããããïŒãã£ãŠæããŸãããin vitroã®ã²ãšã€ã®ç ç©¶ææã®ã¿ããšããããŠãŠã€ã«ã¹ã®å¢æ®ãæãã广ããããšèšã£ãŠããŸã£ãŠããããã®ãªã®ãïŒ
ãã¬ããæ£è ããã«äžãã圱é¿åã¯çµ¶å€§ãªã®ã§ãTVæŸæ ã«ã€ããŠã¯æ¯éèªå€§åºåã«ãªããªããããªæ£ç¢ºãªæ å ±ãæåŸ ããããšæããŸãã
ã¯ã¡ã¿ã€
ã¯ã¡ã¿ã€ãšã¯ããããããè±ã®èãæ¡éããå·£ã®äžã§å å·¥ã貯èµãããã®ããããŸããç°¡åã«èšããšãèãã§ãã
ããã«ãããŒã¯ãã®ã§ãªã¥ãŠãã€ã®è±ããã»ã€ãšãŠããããã«ãã£ãŠæ¡åãããèèã§ãããäž»ã«ãã¥ãŒãžãŒã©ã³ãããªãŒã¹ãã©ãªã¢ãªã©ã§æ œå¹ãããŠããŸãããèŠã¯èã§ãã
æå¹æ§ã«ã€ããŠã¯ãå¹èœã®å¯èœæ§ã瀺åãããŠããã¬ãã«ã§
ã»ç®èã«å¡åžããŠæ²»çã®ä¿é²ïŒã¬ãŒãŒã«ãã¿ããŸããŠäœ¿çšïŒ
ã»å³ãïŒç²æ¶²ã®åæ³ä¿é²ã«ããæ°éã®ä¿æ¹¿ãšèå¯ïŒ
ãå°±å¯åã«ã¯ã¡ã¿ã€ãå°éïŒ2.5ïœ10mLïŒå°ãã0.5ïœ2æ¯ïŒæå
ãâãïŒæ³ä»¥äžã®å°å
ã§å³ç·©å
ãããã¹ããã¡ãããã¡ã³ãšåçã®å¹æ
ãæããããŠããŸãã
çžäºäœçšã«ã€ããŠã¯ããŸã æããã§ã¯ãªããšããã¬ãã«ã§ãã
Pubmedã§ãHoneyã®Drug interactionã«ã€ããŠèª¿ã¹ãŠã¿ããšïŒä»¶ã»ã©ãããããŠããŸããã
Daily honey consumption does not change CYP3A activity in humans.
J Clin Pharmacol. 2011 Aug; 51(8):1223-32. Epub 2010 Dec 8.ïŒPMIDïŒ21148046ïŒ
Effect of concomitantly administered honey on the pharmacokinetics of carbamazepine in healthy volunteers.
Methods Find Exp Clin Pharmacol. 2003 Sep; 25(7):537-40.ïŒPMIDïŒ14571284ïŒ
ããããCYP3A掻æ§ã«é¢é£ãããã®ã®ããã§ããããã©ã¡ãã圱é¿ãäžããªãã£ããšããå 容ã«ãªã£ãŠãããšæããŸãããšã«ããå ±åèªäœãå°ãªãããã¯ã£ããèšããªãã®ãçŸç¶ã§ãã
ããŒã€ã«ãŒãªãŒ
ããŒã€ã«ãŒãªãŒã¯ããããããåæ³ããä¹³çœç¶ã®ç©è³ªã§ããæ§ææåã¯ãæ°ŽåïŒ60ïœ70%ãèçœè³ªïŒ12ïœ15%ãç³è³ªïŒ10ïœ16%ãè質ïŒ3ïœ6%ããã®ä»ãã¿ãã³ãå¡©åãã¢ããé žãšãªã£ãŠããŸãã
ããŒã€ã«ãŒãªãŒãé£ã¹ãããã®ã¯ã嬢çèã ãã§ããããšããããŒã€ã«ãŒãªãŒãšããååãã€ããŠããããã§ãã
æå¹æ§ã«ã€ããŠã¯ãç§åŠçããŒã¿ãäžååãªã¬ãã«ã§ããã
Pubmedã®RCTãªã©ã§ææå·®ãã€ãããšãããŠãããã®ãšããŠ
ã»è質æ¹å广
ã»æŽå¹Žæé害ã®çç¶ç·©å
ã»å£å
çã®æ¹åä¿é²ïŒååŠçæ³ãæŸå°ç·çæ³ïŒ
ã»ãã©ã€ã¢ã€
ã»æçµåçå矀ïŒPMSïŒ
ãªã©ãæããããŠããŸãããã®å¹æã«ã€ããŠã¯ãããªãç ç©¶ãå¿ èŠããã§ãã
çžäºäœçšã«ã€ããŠã¯ãã¯ã«ãã¡ãªã³ãšã®çžäºäœçšãæããããŠããŸãã
Warfarin and royal jelly interaction.
Pharmacotherapy. 2006 Apr; 26(4):583-6.ïŒPMIDïŒ16553520ïŒ
INR1.9ïœ2.4ã§ã³ã³ãããŒã«ãããŠãã87æ³ã¢ã¡ãªã«äººç·æ§ãã宿å蚺ã®ïŒé±éåŸã«è¡å°¿ã§ææ¥éšã«æ¥ãéã«INRãæž¬å®ãããšãã6.88ãŸã§äžæããŠãããå ¥é¢åŸã¯ããã«äžæããŠãããšãããã®ããã®çµéããã©ã£ãŠãããšãããŒã€ã«ãŒãªãŒãšã®å æé¢ä¿ãé«ãçžäºäœçšã®å¯èœæ§ããããšãããã®ã§ãã
ïŒäŸå ±åãªã®ã§äœãšãèšããªããšããã¯ãããŸãããã¯ã«ãã¡ãªã³ã®äœçšãå¢åŒ·ããå¯èœæ§ããããšçµè«ã¥ããããŠããŸãã
ããããªã¹
ããããªã¹ã¯ãèã®å·£ã®ééãåããå°æ¢å€ãšããŠäœ¿ãããŠããŠããããããæšã®èœã暹液ãªã©ããéããæš¹è補混åç©ã§ããå·£ã®è æã»åŸ®çç©ã®æ±æé²æ¢ã»æ¯å軜æžã»è£åŒ·ãªã©ã®ç®çã§äœ¿ãããããã§ãã
æå¹æ§ã«ã€ããŠã¯ãå¹èœã®å¯èœæ§ã瀺åãããŠããã¬ãã«ã§
ã»å£ã®æè¡åŸã®çã¿ãççã®æ²»çã軜æžãä¿é²
ãïŒïŒïŒ
ããããªã¹æ¶²ã§æŽå£ïŒ
ã»æ§åšãã«ãã¹ïŒ3%ããããªã¹è»èïŒæ¥ïŒåå¡åžïŒ
ãæããããŠããŸãã
ãã®ä»ãå ç«èª¿ç¯ãæè «çãæççãæé žåãæèãæãŠã€ã«ã¹ãæçèãæå¯çè«äœçšãªã©ã®çç©åŠçããã³è¬çåŠçç¹æ§ãæåŸ ãããŠããŸãã
çžäºäœçšã«ã€ããŠã¯ããŸã æããã§ã¯ãªããšããã¬ãã«ã§ãã
Pubmedã§ãpropolis ã®Drug interactionã«ã€ããŠèª¿ã¹ãŠã¿ããšïŒã€ãããããŠããŸãã
Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach.
J Ethnopharmacol. 2019 Dec 5;245ïŒPMIDïŒ31442620ïŒ
ã«ãã§ã€ã³ãããµã«ã¿ã³ããªã¡ãã©ãŸãŒã«ãã¡ãããããŒã«ããããŸã©ã ããã§ããœãã§ããžã³ãªã©ãå©çšããŠãããããªã¹æœåºç©ïŒEPP-AFïŒããã®ä»£è¬é µçŽ æŽ»æ§ã«åœ±é¿ãäžãããã詊éšãããã®ã§ããAUCãæžå°ãŸãã¯å¢å ããè¬å€ããããŸãããããã®å·®ã¯çµ±èšåŠçã«ææã§ã¯ãªããCYP1A2ãCYP2C9ãCYP2C19ãCYP2D6ããã³CYP3Aã®æŽ»æ§ãèšåºçã«å€åãããªãããšã瀺ããŠãããšçµè«ã¥ããããŠãããšæããŸãã
ããããçžäºäœçšã¯CYPã«é¢é£ãããã®ã ãã§ããªãããããŸã æªç¥ã®éšåã¯å€ããããŸãã
ãããã«
ãããŸã§ããããã®æå¹æ§ãšçžäºäœçšã«ã€ããŠã¿ãŠããŸããã絶察ã«å€§äžå€«ã§ãããšèšãåãããã®ã¯ãããŸããããçŸæ®µéã®æ å ±ã§ã¯ãã¯ã¡ã¿ã€ãšã¯ã¹ãªã®çžäºäœçšã®å¯èœæ§ã¯äœããšèšããã®ã§ã¯ãªãããšæããŸãã
æ£è ããã®è³ªåããèªåã§èª¿ã¹ãããšã«ããç¥èãšãªã£ãŠç©ã¿éãªãããšãå€ããããŸãããããããå°ããã€æ¯ãè¿ãããŸãšããç¶ããŠãããã°ãšæããŸãã
ãåèè³æïŒå¥åº·é£åã»ãµããªã¡ã³ãã®ãã¹ãŠïŒJahficïŒã